Cover Image

H-1 parvovirus-induced oncolysis and tumor microenvironment immune modulation in a novel heterotypic spheroid model of cutaneous T-cell lymphoma

The rat protoparvovirus H-1 (H-1PV) is an oncolytic virus known for its anticancer properties in laboratory models of various human tumors, including non-Hodgkin lymphomas (NHL) of B-cell origin. However, H-1PV therapeutic potential against hematological malignancies of T-cell origin remains underex...

Full description

Saved in:
Bibliographic Details
Main Authors: Angelova, Assia L. (Author) , Barf, Milena (Author) , Just, Alexandra (Author) , Leuchs, Barbara (Author) , Rommelaere, Jean (Author) , Ungerechts, Guy (Author)
Format: Article (Journal)
Language:English
Published: August-1 2024
In: Cancers
Year: 2024, Volume: 16, Issue: 15, Pages: 1-21
ISSN:2072-6694
DOI:10.3390/cancers16152711
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers16152711
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/16/15/2711
Get full text
Author Notes:Assia Angelova, Milena Barf, Alexandra Just, Barbara Leuchs, Jean Rommelaere and Guy Ungerechts
Description
Summary:The rat protoparvovirus H-1 (H-1PV) is an oncolytic virus known for its anticancer properties in laboratory models of various human tumors, including non-Hodgkin lymphomas (NHL) of B-cell origin. However, H-1PV therapeutic potential against hematological malignancies of T-cell origin remains underexplored. The aim of the present study was to conduct a pilot preclinical investigation of H-1PV-mediated oncolytic effects in cutaneous T-cell lymphoma (CTCL), a type of NHL that is urgently calling for innovative therapies. We demonstrated H-1PV productive infection and induction of oncolysis in both classically grown CTCL suspension cultures and in a novel, in vivo-relevant, heterotypic spheroid model, but not in healthy donor controls, including peripheral blood mononuclear cells (PBMCs). H-1PV-mediated oncolysis of CTCL cells was not prevented by Bcl-2 overexpression and was accompanied by increased extracellular ATP release. In CTCL spheroid co-cultures with PBMCs, increased spheroid infiltration with immune cells was detected upon co-culture treatment with the virus. In conclusion, our preclinical data show that H-1PV may hold significant potential as an ingenious viroimmunotherapeutic drug candidate against CTCL.
Item Description:Veröffentlicht: 30. Juli 2024
Gesehen am 07.04.2025
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers16152711

Similar Items